Skip to main content

Abstract

The First Trial of Cim331, a Humanized Antihuman Interleukin-31 Receptor a Antibody, in Healthy Volunteers and Patients with Atopic Dermatitis to Evaluate Safety, Tolerability and Pharmacokinetics of a Single Dose in a Randomized, Double-Blind, Placebo-Controlled Study

This is a members-only content. Please log in to access it.